Search results

Filters
Close
ADDED DATE
Added date
TOPICS Please select
WATCH / LISTEN / READ TIME
VICTOR Trial: Vericiguat Shows No Benefit for Primary Endpoint in Stable HFrEF
Added: 4 months ago Source:  Radcliffe Cardiology
Results from the Phase III VICTOR trial, presented at the European Society of Cardiology (ESC) Congress 2025 and published in The Lancet, show that vericiguat did not meet its primary endpoint in patients with chronic, stable heart failure with reduced ejection fraction (HFrEF).¹˒²Vericiguat is an oral, once-daily stimulator of soluble guanylate cyclase (sGC), an enzyme in the nitric oxide… View more

Guidelines & Statements

Heart Failure
AHA 23 Late-Breaker Discussion: The ARIES HM3 Clinical Trial
Author(s): Harriette Van Spall , Mandeep Mehra Added: 2 years ago
AHA 23 - Investigator, Dr Mandeep R Mehra (Brigham and Women's Hospital and Harvard Medical School, US) is joined by Late-breaker host, Dr Harriette Van Spall (McMaster University, CA) to discuss the ARIES HM3 trial.ARIES HM3 is a prospective, randomised, double-blinded, placebo-controlled clinical investigation into heart failure (HF) patients treated with the ARIES HeartMate 3 pump, who were… View more

Heart Failure

Electrophysiology & Arrhythmia
ARNI for Optimising HFrEF Management
Author(s): Massimo Iacoviello , Filippo M Sarullo , Claudio Bilato , et al Added: 6 months ago

Heart Failure
Clinical Frailty Scale Predicts Mortality in Heart Failure
Added: 1 week ago Source:  Radcliffe Cardiology
Frailty is a common and significant factor associated with adverse outcomes in patients with heart failure, but the prognostic utility of simple assessment tools in contemporary practice remains an area of investigation. A new study using data from a large Japanese registry has found that the Clinical Frailty Scale (CFS) effectively captures both physical and cognitive decline and is an… View more

Demographic

Heart Failure
AHA 2025: The TIRZSEMA-CVOT Study
Author(s): Nils Krüger Added: 2 months ago
AHA Scientific Sessions 2025 - Dr Nils Krüger (Brigham and Women's Hospital, US) joins us to discuss findings from the TIRZSEMA-CVOT (NCT07096063) study, examining real-world cardiovascular outcomes with tirzepatide and semaglutide in patients with type 2 diabetes at cardiovascular risk.This retrospective cohort study utilized three national US claims databases to evaluate over 887,000 patients… View more

Cardiovascular Renal Metabolic

Heart Failure
Reverse Remodelling, Myocardial Recovery and Remission in Heart Failure with Reduced Ejection Fraction: Clinical Implications and Management Strategies
Author(s): Silas Ramos Furquim , Maria Tereza Sampaio de Sousa Lira , Deborah de Sá Pereira Belfort , et al Added: 1 month ago

Guidelines & Statements

Heart Failure
VAC in HFpEF: Trends and Challenges
Author(s): Tianzong Li , Yiran Luo , Lina Zhao , et al Added: 1 month ago

Heart Failure

Imaging & Diagnostics
Late breaking Clinical Trial Data Addressing Cardiovascular Outcomes in Patients with Diabetes presented at American College of Cardiology Congress
Added: 1 year ago Source:  Radcliffe Cardiology
AUTHOR: Greg GuilloryTwo late-breaking clinical trials addressing cardiovascular outcomes in patients with diabetes were presented this week at the American College of Cardiology meeting in Atlanta, USA. One of these trials looked at the effects of the hyperactivation of the polyol pathway on diabetic cardiomyopathy (DbCM) and the other the effects of chelation therapy in patients with diabetes… View more

Heart Failure

Cardiovascular Renal Metabolic
Transvenous Phrenic Nerve Stimulation in Central Sleep Apnoea/Heart Failure
Author(s): Tarek Bekfani , Joseph D Abraham , William T Abraham Added: 4 months ago

Heart Failure
Aldosterone and Potassium in Heart Failure
Author(s): Laibah Arshad Khan , Adeena Jamil , Stephen J Greene , et al Added: 1 year ago

Heart Failure

Prevention & Chronic Conditions